The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
26 10 2021
Historique:
pubmed: 6 10 2021
medline: 4 2 2022
entrez: 5 10 2021
Statut: ppublish

Résumé

Macrophages sense and respond to pathogens by induction of antimicrobial and inflammatory programs to alert other immune cells and eliminate the infectious threat. We have previously identified the transcription factor IRF1 to be consistently activated in macrophages during Mycobacterium avium infection, but its precise role during infection is not clear. Here, we show that tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) autocrine/paracrine signaling contributes to controlling the intracellular growth of M. avium in human primary macrophages through activation of IRF1 nuclear translocation and expression of IRG1, a mitochondrial enzyme that produces the antimicrobial metabolite itaconate. Small interfering RNA (siRNA)-mediated knockdown of IRF1 or IRG1 increased the mycobacterial load, whereas exogenously provided itaconate was bacteriostatic at high concentrations. While the overall level of endogenous itaconate was low in M. avium-infected macrophages, the repositioning of mitochondria to M. avium phagosomes suggests a mechanism by which itaconate can be delivered directly to M. avium phagosomes in sufficient quantities to inhibit growth. Using mRNA hybridization, we further show that uninfected bystander cells actively contribute to the resolution of infection by producing IL-6 and TNF-α, which, via paracrine signaling, activate IRF1/IRG1 and strengthen the antimicrobial activity of infected macrophages. This mechanism contributes to the understanding of why patients on anti-inflammatory treatment, e.g., with tocilizumab or infliximab, can be more susceptible to mycobacterial disease.

Identifiants

pubmed: 34607464
doi: 10.1128/mBio.02121-21
pmc: PMC8546851
doi:

Substances chimiques

IRF1 protein, human 0
Interferon Regulatory Factor-1 0
Interleukin-6 0
Tumor Necrosis Factor-alpha 0
ACOD1 protein, human EC 4.1.1.-
Carboxy-Lyases EC 4.1.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0212121

Références

Nat Immunol. 2009 Jun;10(6):587-94
pubmed: 19430477
Infect Immun. 2020 Sep 18;88(10):
pubmed: 32719152
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15907-15913
pubmed: 31320588
Cell Metab. 2020 Sep 1;32(3):468-478.e7
pubmed: 32791101
Environ Health Perspect. 1997 Sep;105 Suppl 5:1261-3
pubmed: 9400735
Nat Immunol. 2015 May;16(5):467-75
pubmed: 25774715
Immunology. 1994 Jul;82(3):361-4
pubmed: 7959868
Nature. 2018 Apr;556(7702):501-504
pubmed: 29670287
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15136-41
pubmed: 17018642
PLoS One. 2016 Feb 12;11(2):e0149050
pubmed: 26872335
Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L941-3
pubmed: 11943657
J Leukoc Biol. 2021 Jan;109(1):23-33
pubmed: 32531827
J Infect Dis. 2010 Mar;201(5):783-92
pubmed: 20121435
J Exp Med. 2018 Apr 2;215(4):1035-1045
pubmed: 29511063
PLoS Pathog. 2017 Aug 14;13(8):e1006551
pubmed: 28806745
Cell Rep. 2021 Mar 9;34(10):108756
pubmed: 33691097
Microbiol Spectr. 2016 Oct;4(5):
pubmed: 27763255
J Biol Chem. 2017 Mar 24;292(12):4766-4769
pubmed: 28188288
Microbiol Immunol. 2002;46(11):751-60
pubmed: 12516771
Cold Spring Harb Perspect Med. 2014 Jul 31;4(10):
pubmed: 25081628
Clin Exp Immunol. 1993 Feb;91(2):277-81
pubmed: 8428392
Proc Natl Acad Sci U S A. 1989 Dec;86(24):9936-40
pubmed: 2557635
Immunity. 2013 May 23;38(5):1025-37
pubmed: 23623383
Cell Metab. 2013 Aug 6;18(2):265-78
pubmed: 23931757
Nature. 2018 Apr 5;556(7699):113-117
pubmed: 29590092
Nature. 2011 Apr 28;472(7344):476-80
pubmed: 21525932
Immunobiology. 2012 Oct;217(10):996-1004
pubmed: 22387074
J Chromatogr A. 2014 Nov 28;1370:70-9
pubmed: 25454131
Cell Mol Life Sci. 2017 May;74(9):1625-1648
pubmed: 27866220
Cell Rep. 2021 Mar 23;34(12):108891
pubmed: 33761354
PLoS Biol. 2018 Mar 29;16(3):e2003782
pubmed: 29596410
Cell Metab. 2019 Jan 8;29(1):211-220.e5
pubmed: 30293776
Nat Microbiol. 2019 Jul;4(7):1096-1104
pubmed: 30988429
Clin Chest Med. 2015 Mar;36(1):91-9
pubmed: 25676522
Cell. 2017 Nov 2;171(4):771-782.e11
pubmed: 29056341
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4272-80
pubmed: 26195781
J Cell Mol Med. 2009 Aug;13(8B):2069-2082
pubmed: 18705699
Nat Immunol. 2008 Apr;9(4):378-87
pubmed: 18345002
Nat Chem Biol. 2014 May;10(5):371-7
pubmed: 24657929
Nat Immunol. 2002 Feb;3(2):102
pubmed: 11812978
Infect Immun. 2000 Jun;68(6):3322-6
pubmed: 10816480
PLoS Pathog. 2021 Jan 21;17(1):e1009220
pubmed: 33476326
Microbiology (Reading). 2021 May;167(5):
pubmed: 34020726
PLoS Pathog. 2016 Feb 01;12(2):e1005408
pubmed: 26829557
Mucosal Immunol. 2011 May;4(3):252-60
pubmed: 21430655
Science. 1994 Mar 18;263(5153):1612-5
pubmed: 7510419
Methods Enzymol. 2015;561:171-96
pubmed: 26358905
Immunity. 2013 Sep 19;39(3):454-69
pubmed: 24012417
Cell Metab. 2016 Jul 12;24(1):158-66
pubmed: 27374498
EMBO J. 1994 Apr 15;13(8):1942-9
pubmed: 8168491
N Engl J Med. 2001 Oct 11;345(15):1098-104
pubmed: 11596589
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:278-283
pubmed: 29571119
Emerg Infect Dis. 2009 Oct;15(10):1556-61
pubmed: 19861045
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7820-5
pubmed: 23610393
J Exp Med. 2016 Apr 4;213(4):585-603
pubmed: 27001747
Science. 2020 Jul 24;369(6502):450-455
pubmed: 32703879
Nat Immunol. 2014 Mar;15(3):231-8
pubmed: 24464131
Metabolites. 2020 Feb 19;10(2):
pubmed: 32093075
Infect Immun. 1997 Nov;65(11):4843-9
pubmed: 9353074
Immunol Res. 2006;35(3):179-90
pubmed: 17172645
Microbiol Spectr. 2017 Apr;5(2):
pubmed: 28429679
Nat Metab. 2020 Jul;2(7):594-602
pubmed: 32694786
Eur J Immunol. 2007 Feb;37(2):315-27
pubmed: 17273999
Science. 2019 Nov 1;366(6465):589-593
pubmed: 31672889
J Infect. 2019 Sep;79(3):262-276
pubmed: 31226272

Auteurs

Alexandre Gidon (A)

Centre of Molecular Inflammation Research, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.

Claire Louet (C)

Centre of Molecular Inflammation Research, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.

Lisa Marie Røst (LM)

Department of Biotechnology and Food Science, Faculty of Natural Sciences, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.

Per Bruheim (P)

Department of Biotechnology and Food Science, Faculty of Natural Sciences, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.

Trude Helen Flo (TH)

Centre of Molecular Inflammation Research, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technologygrid.5947.f, Trondheim, Norway.
Department of Infection, St. Olavs Hospital, Trondheim, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH